- Home
- AMPX vs TRVI Comparison
AMPX vs TRVI Comparison
Compare AMPX & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMPX
- TRVI
- Stock Information
- Founded
- AMPX 2008
- TRVI 2011
- Country
- AMPX United States
- TRVI United States
- Employees
- AMPX N/A
- TRVI N/A
- Industry
- AMPX Industrial Machinery/Components
- TRVI Biotechnology: Pharmaceutical Preparations
- Sector
- AMPX Miscellaneous
- TRVI Health Care
- Exchange
- AMPX Nasdaq
- TRVI Nasdaq
- Market Cap
- AMPX 206.4M
- TRVI 211.4M
- IPO Year
- AMPX N/A
- TRVI 2019
- Fundamental
- Price
- AMPX $1.83
- TRVI $4.54
- Analyst Decision
- AMPX Strong Buy
- TRVI Strong Buy
- Analyst Count
- AMPX 7
- TRVI 8
- Target Price
- AMPX $8.17
- TRVI $9.31
- AVG Volume (30 Days)
- AMPX 2.7M
- TRVI 4.0M
- Earning Date
- AMPX 11-07-2024
- TRVI 11-06-2024
- Dividend Yield
- AMPX N/A
- TRVI N/A
- EPS Growth
- AMPX N/A
- TRVI N/A
- EPS
- AMPX N/A
- TRVI N/A
- Revenue
- AMPX $17,480,000.00
- TRVI N/A
- Revenue This Year
- AMPX $132.96
- TRVI N/A
- Revenue Next Year
- AMPX $234.85
- TRVI N/A
- P/E Ratio
- AMPX N/A
- TRVI N/A
- Revenue Growth
- AMPX 196.22
- TRVI N/A
- 52 Week Low
- AMPX $0.61
- TRVI $1.26
- 52 Week High
- AMPX $6.02
- TRVI $4.60
- Technical
- Relative Strength Index (RSI)
- AMPX 49.08
- TRVI 75.02
- Support Level
- AMPX $1.68
- TRVI $2.36
- Resistance Level
- AMPX $1.87
- TRVI $4.60
- Average True Range (ATR)
- AMPX 0.21
- TRVI 0.33
- MACD
- AMPX -0.06
- TRVI 0.21
- Stochastic Oscillator
- AMPX 23.46
- TRVI 92.46
About AMPX Amprius Technologies Inc.
Amprius Technologies Inc is engaged in the production of silicon anodes for high energy density lithium-ion batteries. The company's batteries are used for existing and emerging aviation applications, including unmanned aerial systems, such as drones and high-altitude pseudo satellites. All of its revenues is geographically earned in the United States.
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.